Special Issue "Targeting Cancer Cell Invasion and Metastasis: From Molecular Mechanisms to Therapeutic Opportunities"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 296
Interests: tumor glycobiology; DNA damage response; chemo- and radioresistance; post-translational modifications; tumorigenesis; tumor metastasis
Interests: glioblastoma; lung and breast cancer brain metastasis
Interests: post-translational modifications of cancer proteins and their roles in human cancers; non-coding RNA-mediated cancer and metastasis progression; genetic mouse models of human cancers
Interests: aim to figure out post-translational modifications of important regulatory proteins in the process of tumorigenesis, development, and metastasis, such as methylation, ubiquitination; using gain-of-function and loss-of-function genetic screens in mice to find out key regulator of Tumor metastasis, tumor dormancy and reactivation
Despite recent therapeutic advances in cancer treatment, metastasis, the movement of tumor cells from a primary site to progressively colonize distant organs, is a principal cause of cancer death. Hence, the development of novel therapeutic approaches to effectively inhibit metastasis, as well as target metastatic lesions, is urgently needed.
The aberrant invasion signaling pathways that are activated in metastasis-initiating cells underlie the establishment of metastatic process. Importantly, metastatic cancer cells engage in bidirectional interactions with metastatic microenvironments to alter the extracellular environments, genomic stability, survival signaling, and antitumor immunity, which could eventually result in immuno-, radio-, and chemotherapeutic resistance. Thus, understanding how various regulatory mechanisms are abnormally regulated and sustaining metastasis during these interactions will be of utmost importance.
The current Special Issue invites contributions that provide novel aspects (original research articles and timely reviews) related to cancer metastasis, with special focus, but not limited to: the insights that describe the genomics, transcriptomics, proteomics, metabolomics, and posttranslational modifications-related proteomics with respect to the biology of cancer metastasis; the identification of novel therapeutic targets and mechanisms, for example those that involve ubiquitination, glycosylation, and cell death, for invasion and metastasis based on new strategies (e.g., CRISPR Screening), as well as the ‘linkers’ between cancer chemo-/radio-resistance and metastasis; investigation of the mechanisms involved in the biology of metastasis-initiating cells that results in tumor growth in distant organs, evasion of immune surveillance and co-option of metastatic microenvironments, especially how the cell membrane receptors (e.g., integrins and other glycoproteins) orchestrate metastasis and how the metastatic cells remodel the extracellular matrix; research topics focusing on efforts enabling therapeutic advances (e.g., combining novel therapeutic approaches with existing modalities) in treating both micro- and macrometastases, especially the personalized therapy. Contributions on other significant topics that further enhance our understanding of the biology of cancer invasion and metastasis are also welcome.
Dr. Qinglei Hang
Prof. Dr. Aidong Zhou
Prof. Dr. Jongchan Kim
Dr. Hongqi Teng
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- aberrant signaling
- PTMs - phosphorylation, ubiquitination, methylation, glycosylation
- ECMs - collagens, fibronectin, vitronectin, laminin
- metastasis-initiating cell
- resistance to treatment
- cancer therapeutics